Results 21 to 30 of about 136,514 (310)
Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure [PDF]
, 1993 The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure.
Braun, A. +5 more
core +1 more source
Kidney International, 1999 Serum ferritin concentration is most informative in estimating the amount of storage iron available for a particular individual. The serum transferrin receptor concentration, in contrast to serum ferritin, provides direct information about any deficit in the adequacy of iron supply to the erythropoiesis.
René Gottschalk +1 more
openaire +3 more sources
Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells
Revista Brasileira de Hematologia e Hemoterapia, 2016 Background: Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels.
Oscar Andrés Penuela +2 more
doaj +1 more source
Increased plasma viscosity as a reason for inappropriate erythropoietin formation [PDF]
, 1993 The aim of this study was to examine whether altered plasma viscosity could contribute to the inappropriately low production rate of erythropoietin (EPO) observed in patients suffering from hypergammaglobulinemias associated with multiple myeloma or ...
Eckardt, Kai-Uwe +7 more
core +2 more sources
Cold Spring Harbor Perspectives in Medicine, 2013 During the past century, few proteins have matched erythropoietin (Epo) in capturing the imagination of physiologists, molecular biologists, and, more recently, physicians and patients. Its appeal rests on its commanding role as the premier erythroid cytokine, the elegant mechanism underlying the regulation of its gene, and its remarkable impact as a ...
openaire +2 more sources
Haematologica, 2013 Erythropoiesis stimulating agents are widely used for the treatment of anemia. Recently, we reported erythroid expansion with impaired B lymphopoiesis and loss of trabecular bone in C57BL/6 mice following ten days of treatment with low-dose short acting ...
Sita R. Dewamitta +3 more
doaj +1 more source
The use of genes for performance enhancement: doping or therapy? [PDF]
, 2011 Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation ...
Collares, T. F. +4 more
core +4 more sources
Predictors of hyporesponsiveness to erythropoietin in prevalent hemodialysis patients and its association with mortality [PDF]
Revista Portuguesa de Nefrologia e Hipertensão, 2022 Introduction: Erythropoietin-stimulating agents hyporesponsiveness is common among hemodialysis patients. The aim was to analyze factors predictive of Erythropoietin-stimulating agent resistance and its association with mortality.
Marisa Roldão +5 more
doaj +1 more source
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway [PDF]
, 2003 Objective. Erythropoietin (EPO) is a key regulator of erythropoiesis, playing a role in both the proliferation and differentiation of erythroid cells.
Bieber +36 more
core +1 more source
Initiating haemodialysis twice-weekly as part of an incremental programme may protect residual kidney function [PDF]
, 2019 © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.Background: Initiating twice-weekly haemodialysis (2×HD) in patients who retain significant residual kidney function (RKF) may have benefits.
Busby, Amanda D +7 more
core +1 more source